AI ‘promising’ for use in geriatrics, but ethical concerns remain, researchers say
By
Aaron Dorman
Sep 22, 2023
A new meta-study on using AI within geriatrics praises AI as a “valuable asset” but still warns about the need for future research and potential ethical concerns.
Americans ‘dangerously’ underestimate healthcare costs, challenges in retirement planning
By
Kimberly Bonvissuto
Sep 21, 2023
Americans “dangerously” underestimate the effects that healthcare costs and challenges may have on their retirement plans, including planning for a stay in a long-term care facility, according to the...
Act prioritizes fight against Alzheimer’s disease with state plan
By
Kimberly Bonvissuto
Sep 12, 2023
South Carolina’s adoption of a state Alzheimer’s plan is a “step forward,” according to senior living advocates.
When it comes to virtual reality, imagination often trumps innovation, research finds
By
Aaron Dorman
Aug 28, 2023
When it comes to virtual reality, programming advances in the tech may not be as important to users as what they bring themselves: their imagination.
Brain analyses suggest memory therapy can involve patients’ imagination more than their actual experience
By
Aaron Dorman
Aug 04, 2023
Recent brain research suggests that imagination and recall are just as important as actual experience in reinforcing our memory systems.
Promising Alzheimer’s treatment options lead to expanded PET scan recommendations
By
Aaron Dorman
Jul 24, 2023
CMS is now recommending expanding coverage for PET scans by lifting the current single-test limit.
Composite inflammatory biomarker linked to dementia risk
Jul 21, 2023
Small but significant associations were seen between elevated biomarker levels and worsened cognitive performance.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
Donanemab slows clinical progression in early Alzheimer’s disease
Jul 17, 2023
The drug slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population.
Memory care certification launches for assisted living communities
By
Lois A. Bowers
Jul 12, 2023
The Joint Commission, in collaboration with the Alzheimer’s Association, has launched a memory care certification program for assisted living communities.